scispace - formally typeset
S

Sandra Gawchik

Researcher at Crozer-Keystone Health System

Publications -  12
Citations -  684

Sandra Gawchik is an academic researcher from Crozer-Keystone Health System. The author has contributed to research in topics: Placebo & Asthma. The author has an hindex of 8, co-authored 12 publications receiving 627 citations.

Papers
More filters
Journal ArticleDOI

Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents

TL;DR: Use of once-daily grass AIT treatment effectively treats timothy grass (cross-reactive with Festucoideae grasses) pollen-induced ARC in North American children 5 years and older and might become an important addition to the North American ARC treatment armamentarium.
Journal ArticleDOI

Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.

TL;DR: The general requirements for aspirin desensitization are presented, the locations where desensitizations can be safely performed are outlined, prechallenge patient preparation is discussed, and an oral aspirin challenge protocol is presented.
Journal ArticleDOI

Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray

TL;DR: Mometasone furoate nasal spray is effective and well tolerated in the treatment of daytime cough associated with SAR, and significantly improved total nasal symptoms in both the daytime and nighttime.
Journal ArticleDOI

Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.

TL;DR: Ragweed AIT was effective and well tolerated in ragweed-allergic North American adults and was comparable to placebo during peak season and entire season.
Journal ArticleDOI

Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites

TL;DR: The 6 and 12 SQ-HDM doses of the HDM SLIT tablet MK-8237 were well tolerated, and local AEs were of short duration, according to a phase 1, multicenter, double-blinded, randomized trial in North American children with HDM allergic rhinitis.